Clinical Study Evaluating The Role of Vonoprazan Versus Pantoprazole in Patients With Gastroesophageal Reflux Disease

Inclusion Criteria: * Age 17-60 years. * Both genders. * Patients with a score ≥ 8 on the Gastroesophageal Reflux Disease Questionnaire (Gerd Q) are defined as having GERD and will enroll in this study and it will be done at baseline and after 8 weeks. Exclusion Criteria: * Subjects with history of gastrointestinal disease, gastroduodenal surgery, inflammatory bowel disease and Barrett's esophagus. * Subjects with an earlier or current history of Zollinger-Ellison syndrome, or other gastric acid hypersecretion disorders (gastric or duodenal ulcer). * Subjects with history of total/subtotal gastrectomy and esophageal achalasia. * Subjects with Corona virus disease (COVID19). * Subjects with major cardiological, respiratory, endocrine metabolic disease and neuro-psychological disease. * Pregnancy or lactation. * Subjects with total bilirubin level ≥ 1.2 mg/dl and ALT level \> 100 IU/l. * Subjects with renal impairment (Crcl less than 30 ml/min). * Patients receiving atazanavir sulphate, nelfinavir and rilpivirine hydrochloride due to potential drug interactions.